RCM
MRNA icon

Ravenstone Capital Management’s Moderna MRNA Stock Holding History

Ravenstone Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-99
Closed -$2.81K – 76
2025
Q1 		$2.81K Sell
99
-901
-90% -$32K ﹤0.01% 73
2024
Q4 		$41.6K Buy
+1,000
New +$47.8K 0.02% 70

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ravenstone Capital Management's MRNA Position: Q2 2025 in Review

Ravenstone Capital Management sold out of Moderna (MRNA) in Q2 2025, closing a stake of 99 shares — an estimated $2.81K sold.

Ravenstone Capital Management first reported a position in MRNA in Q4 2024 and held it in 2 quarters. The position peaked at $41.6K in Q4 2024. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Ravenstone Capital Management reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Ravenstone Capital Management sold 99 Moderna shares in Q2 2025, an estimated $2.81K.
  • Ravenstone Capital Management first reported a position in Moderna in Q4 2024 and held it in 2 quarters.
  • Ravenstone Capital Management's Moderna position peaked at $41.6K in Q4 2024.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Ravenstone Capital Management's 13F filing for Q2 2025, filed 26 Jun 2026.